샘플 요청 목록

 카트 문의
시장보고서
상품코드
1797270

세계의 상피성장인자 수용체-비소세포폐암(EGFR-NSCLC) 시장

Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC)
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 283 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

상피성장인자 수용체-비소세포폐암(EGFR-NSCLC) 세계 시장은 2030년까지 101억 달러에 달할 전망

2024년에 75억 달러로 추정되는 상피성장인자 수용체-비소세포폐암(EGFR-NSCLC) 세계 시장은 2024-2030년 분석 기간에 CAGR 5.2%로 성장하여 2030년에는 101억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 오시머티닙은 CAGR 5.4%를 기록하며 분석 기간 종료시에는 45억 달러에 달할 것으로 예측됩니다. 엘로티닙 부문의 성장률은 분석 기간 동안 CAGR 3.9%로 추정됩니다.

미국 시장은 20억 달러로 추정, 중국은 CAGR 8.3%로 성장 예측

미국의 상피성장인자 수용체-비소세포폐암(EGFR-NSCLC) 시장은 2024년에 20억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 8.3%로 성장하여 2030년까지 20억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.5%와 5.2%로 예측됩니다. 유럽에서는 독일이 CAGR 3.4%로 성장할 것으로 예측됩니다.

세계의 EGFR-비소세포폐암(NSCLC) 시장 - 주요 동향과 촉진요인 정리

EGFR 상태가 비소세포폐암 치료 전략에 어떤 영향을 미치는가?

상피세포성장인자수용체(EGFR) 돌연변이는 비소세포폐암(NSCLC), 특히 선암 아형에서 중요한 바이오마커입니다. 이러한 돌연변이는 EGFR 신호전달 경로의 과활성화로 이어져 조절되지 않는 세포분열과 종양 성장을 촉진합니다. 유럽과 미국에서는 비소세포폐암 환자의 약 10-15%, 아시아에서는 최대 40%가 EGFR 돌연변이를 보이기 때문에 개인별 맞춤 치료 계획에 분자 검사가 필수적입니다.

EGFR 돌연변이의 확인은 비정상적인 EGFR 신호전달을 억제하는 표적 치료제, 특히 티로신 키나아제 억제제(TKI)의 사용을 가능하게 했습니다. 이들 약제는 기존 항암화학요법에 비해 무진행 생존기간을 개선하고 독성을 감소시켰습니다. 게피티닙이나 엘로티닙과 같은 1세대 TKI는 T790M과 같은 내성 돌연변이를 극복할 수 있는 오시머티닙과 같은 새로운 약물로 대체되었습니다. 그 결과, EGFR 검사는 현재 임상 종양학 워크플로우에서 비소세포폐암 진단의 표준 요소로 자리 잡았습니다.

표적 치료와 내성 관리를 재구성하는 데 있어 어떤 진전이 이루어지고 있는가?

최근 EGFR 표적 치료의 발전은 약물 선택성 향상, 내성 극복, 부작용 최소화에 초점을 맞추고 있습니다. 오시머티닙과 같은 3세대 TKI는 중추신경계 전이 및 이전 치료에 대한 후천적 내성이 있는 환자에서 효능을 보이고 있습니다. 현재 약물로 효과적으로 대처할 수 없는 희귀한 EGFR 변이 및 복합 변이를 표적으로 하는 4세대 억제제에 대한 연구가 진행 중입니다.

액체 생검 기술은 EGFR 돌연변이 상태를 모니터링하고 내성 돌연변이를 실시간으로 검출하는 비침습적 도구로 부상하고 있습니다. 이러한 도구는 역동적인 치료 조정을 가능하게 하고, 조직 생검에 대한 의존도를 줄여줍니다. TKI와 항혈관신생제, 면역관문억제제 또는 화학요법을 포함한 병용요법도 반응기간을 연장하고 생존기간을 개선하기 위해 연구되고 있습니다. 이러한 치료법의 혁신은 특히 재발 및 진행성 EGFR 변이 비소세포폐암의 치료 전망을 넓혀가고 있습니다.

시장 수요에 영향을 미치는 환자 집단과 의료 시스템은?

EGFR-NSCLC 부문은 돌연변이 유병률이 높은 동아시아 국가에서 특히 중요합니다. 이들 지역에서는 일상적인 분자 프로파일링과 EGFR 억제제를 이용한 조기 치료가 일반적인 임상 관행이 되고 있습니다. 유럽과 미국의 의료 시스템에서 검사 프로토콜이 표준화되고, 상환 정책이 지원됨에 따라 채택이 확대되고 있습니다. 인구 고령화, 폐암 발병률 증가, 유전체 검사에 대한 접근성 증가는 전 세계적으로 적격 환자 발굴을 증가시키는 요인으로 작용하고 있습니다.

학술의료센터와 암치료병원은 연구 시험, 치료 가이드라인 업데이트, 교육 보급 활동을 통해 채택을 이끄는 중심적인 역할을 담당하고 있습니다. 유전자 검사에 대한 환자의 인식과 정밀 종양학에 대한 수요가 증가함에 따라 진단 시점에 EGFR 스크리닝을 더욱 촉진하고 있습니다. 헬스케어 시스템이 가치 기반 치료를 우선시하는 가운데, 바이오마커 기반 치료로의 전환은 특히 건강 결과와 비용 효율성이 교차하는 분야에서 두드러지게 나타나고 있습니다.

EGFR-NSCLC 시장의 성장 원동력은 무엇인가?

EGFR-NSCLC 시장의 성장은 바이오마커의 대중화, 약물 혁신, 정밀 종양학 도입과 관련된 여러 요인에 의해 주도되고 있습니다. 특정 집단에서 EGFR 돌연변이의 높은 비율은 광범위한 검사 및 표적 치료의 채택을 뒷받침하고 있습니다. 내성 및 중추신경계 질환에 대한 효능이 개선된 차세대 TKI의 개발로 치료 기간이 길어지고 환자 예후가 개선되고 있습니다.

동반진단 약물의 통합과 유전체 검사에 대한 상환 지원으로 표적화 가능한 돌연변이의 조기 식별이 강화되고 있습니다. 새로운 EGFR 억제제 임상시험의 확대와 규제 당국의 승인으로 치료 옵션이 증가하고 있으며, 특히 그동안 치료 옵션이 충분하지 않았던 환자군의 치료 옵션이 증가하고 있습니다. 맞춤형 의료와 표적 치료의 임상적 가치에 대한 인식이 높아지면서 의사들의 채용과 시스템 차원의 통합이 강화되고 있습니다. 이러한 요인들이 종합적으로 EGFR-NSCLC 치료 시장에 대한 지속적인 투자와 치료의 진전을 촉진하고 있습니다.

부문

약물 유형(Osimertinib, Erlotinib, Afatinib, Gefitinib, Dacomitinib), 유통 채널(오프라인, 온라인)

조사 대상 기업 사례

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen(Black Diamond Therapeutics)
  • Blueprint Medicines Corp.
  • Boehringer Ingelheim
  • Cullinan Therapeutics
  • Daiichi Sankyo Co., Ltd.
  • Dizal Pharmaceutical
  • Eli Lilly and Company
  • Genentech(Roche Group)
  • Merck & Co., Inc.
  • Mirati Therapeutics
  • Novartis AG
  • Oric Pharmaceuticals
  • Pfizer Inc.
  • Roche(F. Hoffmann-La Roche Ltd.)
  • Takeda Pharmaceutical Company Ltd.
  • Taiho Pharmaceutical Co., Ltd.
  • Zai Lab

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.03

Global Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market to Reach US$10.1 Billion by 2030

The global market for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) estimated at US$7.5 Billion in the year 2024, is expected to reach US$10.1 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Osimertinib, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Erlotinib segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 8.3% CAGR

The Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global EGFR - Non-Small Cell Lung Cancer (NSCLC) Market - Key Trends & Drivers Summarized

How Is EGFR Status Influencing Treatment Strategies in NSCLC?

Epidermal Growth Factor Receptor (EGFR) mutations are a key biomarker in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma subtypes. These mutations lead to overactivation of EGFR signaling pathways, promoting uncontrolled cell division and tumor growth. Approximately 10-15% of NSCLC patients in Western populations and up to 40% in Asian populations exhibit EGFR mutations, making molecular testing critical for personalized treatment planning.

Identification of EGFR mutations has enabled the use of targeted therapies, notably tyrosine kinase inhibitors (TKIs), which inhibit aberrant EGFR signaling. These drugs have improved progression-free survival and reduced toxicity compared to conventional chemotherapy. First-generation TKIs such as gefitinib and erlotinib have given way to newer agents like osimertinib, which can overcome resistance mutations such as T790M. As a result, EGFR testing is now a standard component of NSCLC diagnosis in clinical oncology workflows.

What Advancements Are Reshaping Targeted Therapy and Resistance Management?

Recent advancements in EGFR-targeted therapy focus on enhancing drug selectivity, overcoming resistance, and minimizing adverse effects. Third-generation TKIs such as osimertinib have shown efficacy in central nervous system metastases and in patients with acquired resistance to earlier therapies. Research is ongoing into fourth-generation inhibitors designed to target uncommon EGFR mutations or compound mutations that current drugs cannot address effectively.

Liquid biopsy technologies are emerging as non-invasive tools to monitor EGFR mutation status and detect resistance mutations in real time. These tools enable dynamic treatment adjustment and reduce reliance on tissue biopsy. Combination therapies involving TKIs and anti-angiogenic agents, immune checkpoint inhibitors, or chemotherapy are also being studied to prolong response duration and improve survival. These therapeutic innovations are expanding the treatment landscape for EGFR-mutated NSCLC, particularly in relapsed and advanced-stage patients.

Which Patient Populations and Healthcare Systems Are Impacting Market Demand?

The EGFR-NSCLC segment is especially significant in East Asian countries where mutation prevalence is high. In these regions, routine molecular profiling and early-stage treatment with EGFR inhibitors are common clinical practices. In Western healthcare systems, adoption is growing as testing protocols become standardized and supported by reimbursement policies. Aging populations, rising lung cancer incidence, and growing access to genomic testing are contributing to increased identification of eligible patients globally.

Academic medical centers and cancer treatment hospitals play a central role in guiding adoption through research trials, updated treatment guidelines, and educational outreach. Patient awareness of genetic testing and demand for precision oncology is increasing, further promoting EGFR screening at the point of diagnosis. As healthcare systems prioritize value-based care, the shift toward biomarker-driven treatment is becoming more prominent, especially where health outcomes and cost efficiency intersect.

What Is Driving Growth in the EGFR - NSCLC Market?

Growth in the EGFR-NSCLC market is driven by several factors related to biomarker prevalence, drug innovation, and precision oncology uptake. High rates of EGFR mutations in specific populations are supporting broad testing and targeted therapy adoption. Development of next-generation TKIs with improved efficacy against resistant and CNS-involved disease is expanding treatment duration and improving patient outcomes.

Integration of companion diagnostics and reimbursement support for genomic testing are enhancing early identification of targetable mutations. Expansion of clinical trials and regulatory approvals for novel EGFR inhibitors are increasing treatment options, especially in previously under-addressed patient subsets. Rising awareness of personalized medicine and the clinical value of targeted therapies is strengthening physician adoption and system-level integration. These factors are collectively driving sustained investment and therapeutic advancement in the EGFR-NSCLC treatment market.

SCOPE OF STUDY:

The report analyzes the Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Osimertinib, Erlotinib, Afatinib, Gefitinib, Dacomitinib); Distribution Channel (Offline Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen? (Black Diamond Therapeutics)
  • Blueprint Medicines Corp.
  • Boehringer Ingelheim
  • Cullinan Therapeutics
  • Daiichi Sankyo Co., Ltd.
  • Dizal Pharmaceutical
  • Eli Lilly and Company
  • Genentech (Roche Group)
  • Merck & Co., Inc.
  • Mirati Therapeutics
  • Novartis AG
  • Oric Pharmaceuticals
  • Pfizer Inc.
  • Roche (F. Hoffmann-La Roche Ltd.)
  • Takeda Pharmaceutical Company Ltd.
  • Taiho Pharmaceutical Co., Ltd.
  • Zai Lab

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of NSCLC Globally Drives Sustained Demand for EGFR-Targeted Therapeutics
    • Increased Adoption of Precision Oncology Approaches Strengthens Business Case for EGFR Mutation Testing and Targeted Therapy
    • Advancements in Liquid Biopsy Technologies Accelerate Non-Invasive Detection of EGFR Mutations
    • Expanding Role of Companion Diagnostics Throws Spotlight on Personalized EGFR Therapy Regimens
    • Regulatory Approvals for Next-Generation EGFR Inhibitors Propel Growth in First-Line and Refractory NSCLC Treatment
    • Growing Use of Osimertinib and Other Third-Generation TKIs Spurs Shift in Standard of Care for EGFR-Positive Patients
    • Emerging Resistance Mutations in EGFR Pathways Generate Opportunities for Combination and Sequential Therapy Approaches
    • Expansion of Molecular Testing Programs in Emerging Markets Enhances EGFR Mutation Identification and Drug Uptake
    • Increasing Enrollment in Clinical Trials for Novel EGFR Agents Sustains Innovation Momentum Across Therapeutic Classes
    • Integration of AI in Biomarker Discovery Enhances Targeted Drug Development for EGFR Subtypes in NSCLC
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Osimertinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Osimertinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Osimertinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Erlotinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Erlotinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Erlotinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Afatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Afatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Afatinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gefitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gefitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Gefitinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Dacomitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Dacomitinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Dacomitinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Drug Type - Percentage Breakdown of Value Sales for Osimertinib, Erlotinib, Afatinib, Gefitinib and Dacomitinib for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Epidermal Growth Factor Receptor - Non-Small Cell Lung Cancer (EGFR - NSCLC) by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제